[go: up one dir, main page]

DE122004000007I1 - Monoklonaler Antikörper gegen ein Cytotoxin, denselben erzeugendes Hybridoma und Verfahren für die Herstellung des gereinigten Cytotoxin. - Google Patents

Monoklonaler Antikörper gegen ein Cytotoxin, denselben erzeugendes Hybridoma und Verfahren für die Herstellung des gereinigten Cytotoxin.

Info

Publication number
DE122004000007I1
DE122004000007I1 DE200412000007 DE122004000007C DE122004000007I1 DE 122004000007 I1 DE122004000007 I1 DE 122004000007I1 DE 200412000007 DE200412000007 DE 200412000007 DE 122004000007 C DE122004000007 C DE 122004000007C DE 122004000007 I1 DE122004000007 I1 DE 122004000007I1
Authority
DE
Germany
Prior art keywords
cytotoxin
making
same
monoclonal antibody
purified
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
DE200412000007
Other languages
English (en)
Inventor
David Wallach
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yeda Research and Development Co Ltd
Original Assignee
Yeda Research and Development Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=11055557&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE122004000007(I1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Yeda Research and Development Co Ltd filed Critical Yeda Research and Development Co Ltd
Publication of DE122004000007I1 publication Critical patent/DE122004000007I1/de
Pending legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56972—White blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/525—Tumor necrosis factor [TNF]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Toxicology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
DE200412000007 1984-12-20 1985-12-13 Monoklonaler Antikörper gegen ein Cytotoxin, denselben erzeugendes Hybridoma und Verfahren für die Herstellung des gereinigten Cytotoxin. Pending DE122004000007I1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IL73883A IL73883A (en) 1984-12-20 1984-12-20 Monoclonal antibodies against tnf-alpha,hybridomas producing them and method for the purification of tnf-alpha

Publications (1)

Publication Number Publication Date
DE122004000007I1 true DE122004000007I1 (de) 2004-07-01

Family

ID=11055557

Family Applications (5)

Application Number Title Priority Date Filing Date
DE200412000007 Pending DE122004000007I1 (de) 1984-12-20 1985-12-13 Monoklonaler Antikörper gegen ein Cytotoxin, denselben erzeugendes Hybridoma und Verfahren für die Herstellung des gereinigten Cytotoxin.
DE3586536T Expired - Lifetime DE3586536T3 (de) 1984-12-20 1985-12-13 Monoklonaler Antikörper gegen ein Cytotoxin, denselben erzeugendes Hybridoma und Verfahren für die Herstellung des gereinigten Cytotoxin.
DE19853586536 Pending DE122004000005I1 (de) 1984-12-20 1985-12-13 Monoklonaler Antik¦rper gegen ein Cytotoxin, denselben erzeugendes Hybridoma und Verfahren f}r die Herstellung des gereinigten Cytotoxin
DE198585115918T Pending DE186833T1 (de) 1984-12-20 1985-12-13 Zytotoxisches protein, verfahren zum isolieren desselben, monoklonaler antikoerper ct-1 und denselben erzeugendes hybridoma.
DE200412000017 Pending DE122004000017I1 (de) 1984-12-20 1985-12-13 Monoklonaler Antik¦rper gegen ein Cytotoxin, denselben erzeugendes Hybridoma und Verfahren f}r die Herstellung des gereinigten Cytotoxin.

Family Applications After (4)

Application Number Title Priority Date Filing Date
DE3586536T Expired - Lifetime DE3586536T3 (de) 1984-12-20 1985-12-13 Monoklonaler Antikörper gegen ein Cytotoxin, denselben erzeugendes Hybridoma und Verfahren für die Herstellung des gereinigten Cytotoxin.
DE19853586536 Pending DE122004000005I1 (de) 1984-12-20 1985-12-13 Monoklonaler Antik¦rper gegen ein Cytotoxin, denselben erzeugendes Hybridoma und Verfahren f}r die Herstellung des gereinigten Cytotoxin
DE198585115918T Pending DE186833T1 (de) 1984-12-20 1985-12-13 Zytotoxisches protein, verfahren zum isolieren desselben, monoklonaler antikoerper ct-1 und denselben erzeugendes hybridoma.
DE200412000017 Pending DE122004000017I1 (de) 1984-12-20 1985-12-13 Monoklonaler Antik¦rper gegen ein Cytotoxin, denselben erzeugendes Hybridoma und Verfahren f}r die Herstellung des gereinigten Cytotoxin.

Country Status (9)

Country Link
US (1) US6090923A (de)
EP (1) EP0186833B2 (de)
JP (2) JPS61191620A (de)
AU (1) AU601144B2 (de)
CA (1) CA1337518C (de)
DE (5) DE122004000007I1 (de)
IL (1) IL73883A (de)
NL (1) NL300142I2 (de)
ZA (1) ZA859757B (de)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5019385A (en) * 1984-11-09 1991-05-28 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Novel lymphopine LK 2 and pharmaceutic compositions containing same
DE3631229A1 (de) * 1986-09-13 1988-03-24 Basf Ag Monoklonale antikoerper gegen humanen tumornekrosefaktor (tnf) und deren verwendung
JP3155961B2 (ja) * 1987-12-30 2001-04-16 煕 中島 抗ビリルビンモノクローナル抗体固定担体およびその製造方法
WO1989009831A1 (en) * 1988-04-15 1989-10-19 Research Corporation Technologies, Inc. Lak cell cytotoxin
EP0486526B2 (de) 1989-08-07 2001-03-07 Peptech Limited Bindeligande für tumornekrosisfaktor
US20030225254A1 (en) 1989-08-07 2003-12-04 Rathjen Deborah Ann Tumour necrosis factor binding ligands
IL99120A0 (en) * 1991-08-07 1992-07-15 Yeda Res & Dev Multimers of the soluble forms of tnf receptors,their preparation and pharmaceutical compositions containing them
ATE172880T1 (de) * 1992-08-28 1998-11-15 Bayer Ag Verwendung von monoklonalen anti-tnf-antikörpern für die behandlung von bakteriellen meningitiden
ATE237808T1 (de) * 1992-10-21 2003-05-15 Stefan Miltenyi Direkte auswahl von zellen durch ein aussheidungsprodukt
US7166423B1 (en) 1992-10-21 2007-01-23 Miltenyi Biotec Gmbh Direct selection of cells by secretion product
IL114615A0 (en) 1995-07-16 1995-11-27 Yeda Res & Dev Modulators of the function of fas receptors and other proteins
US6090382A (en) 1996-02-09 2000-07-18 Basf Aktiengesellschaft Human antibodies that bind human TNFα
CZ292465B6 (cs) 1996-02-09 2003-09-17 Abbott Laboratories (Bermuda) Ltd. Lidské protilátky k lidskému TNFalfa
IL126024A0 (en) * 1998-03-19 1999-05-09 Yeda Res & Dev Modulators of the function of receptors of the tnf/ngf receptor family and other proteins
IL178921A0 (en) * 1998-12-24 2007-03-08 Yeda Res & Dev Caspase-8 interacting proteins
CA2868614A1 (en) 2001-06-08 2002-12-08 Abbott Laboratories (Bermuda) Ltd. Methods of administering anti-tnf.alpha. antibodies
US20050271663A1 (en) * 2001-06-28 2005-12-08 Domantis Limited Compositions and methods for treating inflammatory disorders
US20060073141A1 (en) * 2001-06-28 2006-04-06 Domantis Limited Compositions and methods for treating inflammatory disorders
EP1450839A4 (de) * 2001-11-06 2009-06-24 Serono Lab Verfahren zur behandlung von auf östrogen ansprechendem brustkrebs
US20030206898A1 (en) 2002-04-26 2003-11-06 Steven Fischkoff Use of anti-TNFalpha antibodies and another drug
US20040033228A1 (en) 2002-08-16 2004-02-19 Hans-Juergen Krause Formulation of human antibodies for treating TNF-alpha associated disorders
AU2003265361A1 (en) * 2002-08-28 2004-03-19 Pharmacia Corporation Stable ph optimized formulation of a modified antibody
WO2004019860A2 (en) * 2002-08-28 2004-03-11 Pharmacia Corporation Formulations of modified antibodies and methods of making the same
MY150740A (en) 2002-10-24 2014-02-28 Abbvie Biotechnology Ltd Low dose methods for treating disorders in which tnf? activity is detrimental
AU2003298816C1 (en) * 2002-12-02 2010-12-16 Amgen Fremont, Inc. Antibodies directed to Tumor Necrosis Factor and uses thereof
CN104774931B (zh) 2004-03-31 2017-11-10 综合医院公司 测定癌症对表皮生长因子受体靶向性治疗反应性的方法
TWI556829B (zh) 2004-04-09 2016-11-11 艾伯維生物技術有限責任公司 用於治療ＴＮＦα相關失調症之多重可變劑量療法
CA2903138A1 (en) 2005-05-16 2006-11-23 Abbvie Biotechnology Ltd. Use of tnfa inhibitor for treatment of erosive polyarthritis
EP2004689A4 (de) 2006-04-05 2010-06-02 Abbott Biotech Ltd Antikörperreinigung
US9605064B2 (en) 2006-04-10 2017-03-28 Abbvie Biotechnology Ltd Methods and compositions for treatment of skin disorders
EP2007426A4 (de) 2006-04-10 2010-06-16 Abbott Biotech Ltd Anwendungen und zusammensetzungen zur behandlung von psoriasis-arthritis
WO2007120656A2 (en) 2006-04-10 2007-10-25 Abbott Biotechnology Ltd. Uses and compositions for treatment of rheumatoid arthritis
WO2008140449A1 (en) 2007-05-11 2008-11-20 Thomas Jefferson University Methods of treatment and prevention of neurodegenerative diseases and disorders
EP2155225B1 (de) 2007-05-11 2015-07-08 The Trustees of the University of Pennsylvania Verfahren zur behandlung von hautgeschwüren
CA2683801A1 (en) * 2007-06-06 2008-12-11 Domantis Limited Polypeptides, antibody variable domains and antagonists
US8999337B2 (en) 2007-06-11 2015-04-07 Abbvie Biotechnology Ltd. Methods for treating juvenile idiopathic arthritis by inhibition of TNFα
WO2009083246A1 (en) 2007-12-31 2009-07-09 Bayer Schering Pharma Aktiengesellschaft Antibodies to tnf alpha
KR20100120289A (ko) 2008-01-15 2010-11-15 애보트 게엠베하 운트 콤파니 카게 분말상 단백질 조성물 및 이의 제조 방법
EP2228652A1 (de) 2009-03-11 2010-09-15 Medizinische Universität Wien Verbesserung bei der Tumorbehandlung
US9062106B2 (en) 2011-04-27 2015-06-23 Abbvie Inc. Methods for controlling the galactosylation profile of recombinantly-expressed proteins
JP6081995B2 (ja) 2011-06-17 2017-02-15 プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ 癌の処置における治療抗体の標的としてのＦｒｉｚｚｌｅｄ２
US20140227293A1 (en) 2011-06-30 2014-08-14 Trustees Of Boston University Method for controlling tumor growth, angiogenesis and metastasis using immunoglobulin containing and proline rich receptor-1 (igpr-1)
US9334319B2 (en) 2012-04-20 2016-05-10 Abbvie Inc. Low acidic species compositions
US9067990B2 (en) 2013-03-14 2015-06-30 Abbvie, Inc. Protein purification using displacement chromatography
US9181572B2 (en) 2012-04-20 2015-11-10 Abbvie, Inc. Methods to modulate lysine variant distribution
US9249182B2 (en) 2012-05-24 2016-02-02 Abbvie, Inc. Purification of antibodies using hydrophobic interaction chromatography
US9206390B2 (en) 2012-09-02 2015-12-08 Abbvie, Inc. Methods to control protein heterogeneity
US9512214B2 (en) 2012-09-02 2016-12-06 Abbvie, Inc. Methods to control protein heterogeneity
SG11201507230PA (en) 2013-03-12 2015-10-29 Abbvie Inc Human antibodies that bind human tnf-alpha and methods of preparing the same
WO2014151878A2 (en) 2013-03-14 2014-09-25 Abbvie Inc. Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosacharides
US8921526B2 (en) 2013-03-14 2014-12-30 Abbvie, Inc. Mutated anti-TNFα antibodies and methods of their use
US9017687B1 (en) 2013-10-18 2015-04-28 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same using displacement chromatography
EP3708184A1 (de) 2013-03-27 2020-09-16 The General Hospital Corporation Verfahren und mittel zur behandlung von morbus alzheimer
WO2015051293A2 (en) 2013-10-04 2015-04-09 Abbvie, Inc. Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
US9181337B2 (en) 2013-10-18 2015-11-10 Abbvie, Inc. Modulated lysine variant species compositions and methods for producing and using the same
US9085618B2 (en) 2013-10-18 2015-07-21 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
US8946395B1 (en) 2013-10-18 2015-02-03 Abbvie Inc. Purification of proteins using hydrophobic interaction chromatography
US20150139988A1 (en) 2013-11-15 2015-05-21 Abbvie, Inc. Glycoengineered binding protein compositions
KR102617137B1 (ko) 2014-09-15 2023-12-27 칠드런'즈 메디컬 센터 코포레이션 히스톤 h3-리신 트리메틸화를 제거함으로써 체세포 핵 이식(scnt) 효율을 증가시키는 방법 및 조성물
AU2020480890A1 (en) 2020-12-09 2023-07-27 Hk Inno.N Corporation ANTI-OX40L ANTIBODY, ANTI-OX40L/ANTI-TNFα BISPECIFIC ANTIBODY, AND USES THEREOF

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS4843841B1 (de) * 1969-09-06 1973-12-21
GB1541435A (en) * 1975-02-04 1979-02-28 Searle & Co Immunological materials
US5700466A (en) * 1981-09-08 1997-12-23 The Rockefeller University Method of ameliorating or preventing septic shock using a monoclonal antibody specific to cachectin/tumor necrosis factor
AU560087B2 (en) * 1981-09-08 1987-03-26 Rockefeller University, The Lipoprotein lipase suppression by endotoxin-induced mediator (shock assay)
JPS58138383A (ja) † 1982-02-13 1983-08-17 Nippon Shinyaku Co Ltd 生理活性物質の製法
EP0117705A3 (de) * 1983-02-24 1985-09-25 The Regents Of The University Of California Monocyten und Blastzellen spezifischer monoklonaler Antikörper
JPH0780914B2 (ja) * 1984-04-02 1995-08-30 旭化成工業株式会社 ヒト腫瘍壊死因子に対する抗体
US4879226A (en) * 1984-04-06 1989-11-07 Asahi Kasei Kogyo Kabushiki Kaisha Novel human physiologically active polypeptide
NZ212207A (en) * 1984-05-31 1991-07-26 Genentech Inc Recombinant lymphotoxin
GR851626B (de) * 1984-07-05 1985-11-26 Genentech Inc
US5672347A (en) * 1984-07-05 1997-09-30 Genentech, Inc. Tumor necrosis factor antagonists and their use
JPS61124392A (ja) * 1984-11-22 1986-06-12 Asahi Chem Ind Co Ltd 遺伝子組換体の産生する生理活性物質の精製法
US4684623A (en) * 1985-05-02 1987-08-04 The Board Of Trustees Of The Cetus Corporation Use of tumor necrosis factor as a weight regulator
ES2159529T5 (es) * 1993-03-05 2011-03-09 Bayer Corporation Anticuerpos monoclonales humanos anti-tnf alfa.

Also Published As

Publication number Publication date
AU601144B2 (en) 1990-09-06
ZA859757B (en) 1986-09-24
NL300142I1 (nl) 2004-04-01
IL73883A0 (en) 1985-03-31
JPH0787966A (ja) 1995-04-04
DE3586536T2 (de) 1993-02-18
IL73883A (en) 1990-12-23
EP0186833A2 (de) 1986-07-09
US6090923A (en) 2000-07-18
CA1337518C (en) 1995-11-07
EP0186833A3 (en) 1987-05-27
DE122004000017I1 (de) 2005-06-16
EP0186833B1 (de) 1992-08-19
DE186833T1 (de) 1986-12-18
DE122004000005I1 (de) 2006-06-08
EP0186833B2 (de) 2001-11-28
DE3586536D1 (de) 1992-09-24
AU5142485A (en) 1986-06-26
NL300142I2 (nl) 2005-08-01
DE3586536T3 (de) 2002-05-08
JPS61191620A (ja) 1986-08-26

Similar Documents

Publication Publication Date Title
DE122004000007I1 (de) Monoklonaler Antikörper gegen ein Cytotoxin, denselben erzeugendes Hybridoma und Verfahren für die Herstellung des gereinigten Cytotoxin.
DE3587360D1 (de) Verfahren zur herstellung von chimaerischen monoklonalen antikoerpern.
AT369750B (de) Verfahren zur herstellung des neuen 11-aza-4-0cladinosyl-6-0-desosaminyl-15-aethyl-7,13,14-
DE3689734D1 (de) Gereinigter immunoglobulinbezüglicher Faktor, monoklonale Antikörper, Hybridoma-Zellinien, Verfahren und Verwendungen.
DE3581563D1 (de) Polysiloxanpfropfcopolymer und verfahren zu dessen herstellung.
ATA9782A (de) Verfahren zur herstellung des neuen d-phenylalanyl-l-prolyl-l-arginin-aldehyd-sulfa s
DE3582110D1 (de) Verdickungsmittel, verfahren zur herstellung und ihre verwendung.
DE68913402D1 (de) Antikörper mit hoher Affinität für Methamphetamine sowie geeignetes Immunogen für seine Herstellung.
ATE193733T1 (de) Stahl für die herstellung von teilbaren maschinenteilen und maschinenteile, hergestellt aus diesen stahl
FI853283A7 (fi) Uudet monoklonaaliset glykokonjugaattien vasta-aineet, menetelmät niiden tuottamiseksi, ja niiden käytöt.
DE69418581D1 (de) Verfahren zur herstellung dünner bleche, geeignet für die anfertigung von dosenteilen
DE3485054D1 (de) Candida albicans zytoplasmaantigen, monoklonale antikoerper dagegen und verfahren zur herstellung.
DE3581288D1 (de) Antileishmania monoklonale antikoerper, diese antikoerper ausscheidende hybridomas, von diesen antikoerpern erkannte leishmaniaantigene, verfahren zur herstellung und verwendung von diesen monoklonalen antikoerpern und antigenen.
ATA232384A (de) Verfahren zur herstellung neuer 1,5-benzothiazepine
DE3576359D1 (de) Verfahren zur herstellung von tumorspezifische monoklonale antikoerper produzierenden hybridomazellen.
DE69112013D1 (de) Harzzusammensetzung und Verfahren für ihre Herstellung.
AT399885B (de) Verfahren zur herstellung von zellinien, die monoklonale antikörper produzieren
AT373892B (de) Verfahren zur herstellung des neuen kristallinen 1,1-dioxopenicillanoyloxymethyl-6-(d-alpha-amin
ATA160984A (de) Verfahren zur herstellung des neuen antitumor- antibiotikum-komplexes bbm-1675
AT350071B (de) Verfahren zur herstellung des neuen 3,5,5- trimethylhexanoyl-ferrocens
EP0166458A3 (en) Monoclonal antibody capable of specifically distinguishing human hepato-carcinoma cells
AT377698B (de) Verfahren zur herstellung von anti-t.lymphozyten -globulin
DE3584479D1 (de) Synthetisches fraipontit und verfahren zu seiner herstellung.
DE69840561D1 (de) Monoklonaler antikörper, spezifisch für anti-humanes fibrinmonomer, verfahren zur herstellung dessel
DE3577869D1 (de) Neue metallkomplexe, verfahren zu deren herstellung und verwendung.